Olmesartan Medoxomil

奥美沙坦酯

Report date: 2022/07/08 10:55:15
NME

Base Information

Drug NameOlmesartan Medoxomil
Drug Alias Name奥美沙坦美索酯IxiaOlmecOlmesVotum +[24] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1
Therapy Area/IndicationsIschemic StrokeMetabolic SyndromeDiabetes Mellitus, Type 2 +[15] 
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2002/04/25
Country/TerritoryCzechiaBelgiumZambia +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin Gloria Anbo Pharmaceutical Co LtdCosette Pharmaceuticals IncDaiichi Sankyo Co Ltd +[4] 
Inactive CompaniesMylan Pharmaceuticals IncTorrent Pharmaceuticals LtdDaiichi Sankyo Europe Gmbh +[7] 
Active IndicationsHypertension
Inactive IndicationsIschemic StrokeMetabolic SyndromeDiabetes Mellitus, Type 2 +[14] 

Other Information

ATC CodeC09CA08
Related LinksWikipediaDrugBankKEGG